Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: Case report and review of literature

Breast Cancer Research and Treatment

Volumn 141, Issue 2, 2013, Pages 167-172

  Teplinsky, Eleonora ^a   Cheung, Derrick ^b   Weisberg, Ilan ^b   Jacobs, Ramon E A ^c   Wolff, Martin ^b   Park, James ^b   Friedman, Kent ^c   Muggia, Franco ^a   Jhaveri, Komal ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Everolimus; Hepatitis B virus

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; PACLITAXEL; TENOFOVIR; VIRUS DNA;

ACUTE KIDNEY FAILURE; ADULT; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOVIRUS INFECTION; FATALITY; FATIGUE; FEMALE; HEPATITIS B; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LUNG NODULE; LYMPHADENOPATHY; MEDIASTINUM LYMPH NODE; MOUTH PAIN; MUSCLE METASTASIS; PANCREAS DISEASE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHINOVIRUS INFECTION; SCREENING TEST; SIDE EFFECT; TREATMENT DURATION; TUMOR BIOPSY; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CULTURE; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SIROLIMUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84885314840     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2681-0     Document Type: Review

References (37)

1. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529. doi: 10.1056/NEJMoa1109653
2. Pazdur R (2013) FDA Approval of everolimus. http://www.cancer.gov/ cancertopics/druginfo/fda-everolimus. Accessed 15 Aug 2013
3. AFINITOR Package insert. Novartis Pharma
4. Sezgin Goksu S, Bilal S, Coskun HS (2013) Hepatitis B reactivation related to everolimus. World J Hepatol 5(1):43-45. doi: 10.4254/wjh.v5.i1.43
5. Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T (2013) Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 6(2):188-192. doi: 10.1007/s12328-013-0371-4
6. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New Eng J Med 364(6):514-523. doi: 10.1056/NEJMoa1009290
7. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Eng J Med 363(19):1801-1811. doi: 10.1056/NEJMoa1001671
8. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125-132. doi: 10.1016/S0140-6736(12)61134-9
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456. doi: 10.1016/S0140-6736(08)61039-9
10. Oketani M, Ido A, Uto H, Tsubouchi H (2012) Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42(7):627-636. doi: 10.1111/j.1872-034X.2012.00998.x
11. Maynard JE (1990) Hepatitis B: global importance and the need for control. Vaccine 8 (Suppl):S18-S20
12. Lok ASF, McMahon BJ (2009) AASLD Practice guideline update: chronic hepatitis B: update 2009. http://www.aasld.org/practiceguidelines/Documents/ Bookmarked%20Practice%20Guidelines/Chronic-Hep-B-Update-2009%208-24-2009.10. 1007/s10549-013-2681-0. Accessed 15 Aug 2013
13. Kowdley KVWCC, Welch S, Roberts H, Brosgart CL (2012) Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 56(2):422-433. doi: 10.1002/hep.24804
14. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70(4):553-561. doi: 10.1002/jmv.10430
15. Shoushtari AH, Shaw RA (2013) Fulminant hepatitis following chemotherapy treatment for breast cancer. BMJ Case Rep. doi: 10.1136/bcr-2012-007017
16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100(1):182-188
17. Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49(5 Suppl):S156-S165. doi: 10.1002/hep.22945
18. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, Italian Association for the Study of the Liver (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39(5):397-408. doi: 10.1016/j.dld.2006.12.017
19. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116(20):4769-4776. doi: 10.1002/cncr.25253
20. Knoll A, Boehm S, Hahn J, Holler E, Jilg W (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33(9):925-929. doi: 10.1038/sj.bmt. 1704457
21. Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108(10):1931-1935. doi: 10.1038/bjc.2013.225
22. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79(5):616-619
23. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90(7):1306-1311. doi: 10.1038/sj.bjc.6601699
24. Manzano-Alonso ML, Castellano-Tortajada G (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 17(12):1531-1537. doi: 10.3748/wjg.v17.i12.1531
25. Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ (2011) Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 54(4):1199-1207. doi: 10.1002/hep.24529
26. Recommendations for routine testing and follow-up for chronic hepatitis B virus (HBV) infection. Centers for disease control and prevention. http://www.cdc.gov/hepatitis/hbv/PDFs/ChronicHepBTestingFlwUp.pdf. Accessed 15 Aug 2013
27. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL (2010) American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28(19):3199-3202. doi: 10.1200/JCO.2010.30.0673
28. Everolimus (RAD001) in Metastatic transitional cell carcinoma of the urothelium, NCT00805129. http://clinicaltrials.gov/show/NCT00805129. Accessed 15 Aug 2013
29. Study of everolimus added to combined hormonal and radiation therapy for high risk prostate cancer, NCT01642732. http://clinicaltrials.gov/show/ NCT01642732. Accessed 15 Aug 2013
30. Everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumors (GI or Lung Origin) (RADIANT-4), NCT01524783. http://clinicaltrials.gov/show/ NCT01524783. Accessed 15 Aug 2013
31. S1207 Hormone therapy with or without everolimus in treating patients with breast cancer, NCT01674140. http://clinicaltrials.gov/ct2/show/NCT01674140? term=swog+1207&rank=1. Accessed 15 Aug 2013
32. Phase III Study of RAD001 Adjuvant Therapy in poor risk patients with diffuse large B-cell lymphoma (DLBCL) of RAD001 versus matching placebo After patients have achieved complete response with first-line rituximab-chemotherapy (PILLAR2), NCT00790036. http://clinicaltrials.gov/show/NCT00790036. Accessed 15 Aug 2013
33. Daily everolimus in combination with trastuzumab and vinorelbine in HER2/neu positive women with locally advanced or metastatic breast cancer (BOLERO-3), NCT01007942. http://clinicaltrials.gov/show/NCT01007942. Accessed 15 Aug 2013
34. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+Metastatic breast cancer (Bolero-4), NCT01698918. http://clinicaltrials.gov/show/NCT01698918. Accessed 15 Aug 2013
35. A phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer. (BOLERO-6), NCT01783444. http://clinicaltrials.gov/show/NCT01783444. Accessed 15 Aug 2013
36. Porta C, Osanto S, Ravaud A, Climent M-A, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47(9):1287-1298. doi: 10.1016/j.ejca.2011.02. 014
37. European Association for the Study of the Liver (2009) Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50(2):227-242. doi: 10.1016/j.jhep.2008.10.001